Renagel: profile and news
Genzyme targets less-exotic diseases It reports growth in core ... 16 May 2006
Another recent acquisition gave it Renagel, a drug for kidney dialysis patients that could hit $500 million in annual sales this year. ... - Boston Globe,
Genzyme says petition against Renagel ‘inaccurate’ May 12, 2006
...—A recent petition to the US Food and Drug Administration calling for the withdrawal of Genzyme Corp.’s phosphorus drug Renagel was characterized as ... - Renal Business Today,
Doctor calls for withdrawal of Renagel May 11, 2006
BOSTON--Dialysis patients using the phosphorus drug Renagel might be at an increased risk of digestive-tract side effects and death, according to a petition ... - Renal Business Today,
Genzyme's Near-Term Growth Seen Driven By Renagel Apr 20, 2006
..."We continue to expect near-term growth to be driven largely by Renagel (due to impact of DCOR and Medicare Part D), Fabrazyme, Synvisc, and to a lesser extent ... - Forbes
New anti-smoking drug may rival Nabi vaccine May 11, 2006
...a doctor at the University of Texas filed a petition last week with the FDA, asking the agency to withdraw its approval of Genzyme Corp.'s Renagel tablets for ... - Palm Beach Post,
Doctor urges withdrawal of Genzyme kidney drug May 11, 2006
Genzyme Corp.'s kidney-dialysis treatment Renagel may raise the risk of digestive-tract side effects and deaths and should be withdrawn, a doctor said in a ... - Boston Globe,
Genzyme Reports Financial Results for the First Quarter of 2006 Apr 19, 2006
..."We made important progress on many fronts this quarter. Most of our key products performed well, particularly Renagel, which showed very strong growth. ... - MSN Money
A Biotech Feels Its Age May 9, 2006
There's some Street buzz around the renal product line and the revenue leader for that line, the kidney disease treatment Renagel. ... - Smartmoney.com
Genzyme's First-Quarter Sales Below Expectations Apr 19, 2006
...memory with this stock than with some others," he added, referring to 2001's inventory screw-up and temporary shortage of Renagel (sevelamer hydrochloride ... - BioWorld Online (subscription),
Amgen's Sales Fall Short Again Apr 19, 2006
Renagel, a kidney disease drug, had sales of $118.7 million, up 19% from last year and within the range that analysts were estimating, between $115 million and ... - TheStreet.com
Eye On Stocks For Friday, May 12 May 11, 2006
...it expects the company to address a recent filing of a "citizen's petition" with the US Food and Drug Administration requesting Genzyme's Renagel be taken off ... - Forbes
Genzyme 1Q Profit Rises 6 Percent Apr 19, 2006
...$629.9 million last year, with sales of Gaucher disease treatment Cerezyme up 6 percent to $239 million, and sales of kidney disease treatment Renagel up 19 ... - Houston Chronicle,
Genzyme "outperform," target price reduced May 8, 2006
In a research note published this morning, the analysts mention that a recent nephrologist survey indicates that the company’s Renagel and Hectorol drugs are ... - newratings.com
Genzyme profit, sales miss estimates, shares drop Apr 19, 2006
Sales of the company's kidney disease drug Renagel rose 19 percent to $118.7 million, driven by increased demand worldwide. Continued ... - Reuters
Big Pharma Boosted By Q1 Earnings Apr 22, 2006
..."We continue to expect near-term growth to be driven largely by Renagel (due to impact of DCOR and Medicare Part D), Fabrazyme, Synvisc and, to a lesser extent ... - Forbes
Genzyme "neutral weight," target price reduced Apr 19, 2006
According to the analyst, there are initial indications of a positive impact of the Medicare Part D programme on the sales of Renagel. ... - newratings.com
Zacks Bull and Bear of the Day Highlights: Linear Technology ... Apr 24, 2006
Launch of Myozyme in 2006 will further support growth. Yet sales of the company's other key products, Cerezyme and Renagel are maturing. ... - Black Enterprise,
